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MicroarchitectureIn type 1 diabetes, diabetic bone disease (DBD) is characterized by decreased bonemineral density, a state of low
bone turnover and an increased risk of fracture. Animal models of DBD demonstrate that acquired alterations in
trabecular and cortical bone microarchitecture contribute to decreased bone strength in diabetes. With anti-
collagenolytic and anti-inﬂammatory properties, tetracycline derivativesmay prevent diabetes-relateddecreases
in bone strength. To determine if doxycycline, a tetracycline class antibiotic, can prevent the development of DBD
in a model of long-term diabetes, male DBA/2J mice, with or without diabetes, were treated with doxycycline-
containing chow for 10 weeks (dose range, 28–92mg/kg/day). Long-term doxycycline exposure was not delete-
rious to the microarchitecture or biomechanical properties of healthy bones in male DBA/2J mice. Doxycycline
treatment also did not prevent or alleviate the deleterious changes in trabecularmicroarchitecture, cortical struc-
ture, and biomechanical properties of bone induced by chronic diabetes.
© 2014 Elsevier Inc. All rights reserved.1. Introduction
Type 1 diabetes (T1D) has detrimental effects on the skeleton,
resulting in decreased bone formation and enhanced risk of fracture
(Vestergaard et al., 2009; Thrailkill et al., 2005). The underlyingmecha-
nisms leading to skeletal fragility in T1D are likelymultifactorial, but are
associated with decreased endogenous insulin production, hyperglyce-
mia, inﬂammation, and alterations in systemic hormones, such as
insulin-like growth factor-1 (IGF-1) (Thrailkill et al., 2005; Fowlkes
et al., 2011;Motyl et al., 2009).Members of the tetracycline family of an-
tibiotics have been shown to reduce bone loss related to periodontal
disease in animalmodels of T1D (Rifkin et al., 1993).While these antibi-
otics may be useful to prevent bacterial infections, they may also pre-
vent bone breakdown due to their inhibition of collagenases (Rifkin
et al., 1993). In a short-term streptozotocin (STZ)-induced diabetic rat
model, minocycline, a tetracycline derivative, prevented cancellous
bone loss and protected against a decrease in bone formation rates, as
assessed for cancellous bone of the peripheral skeleton (Bain et al.,
1997). While these studies have shown positive effects of tetracyclinel, 1 Children's Way, Slot 512-6,
hrailkill).derivatives on boney tissues inmodels of diabetes, other studies suggest
greater ambivalence regarding the ability of tetracycline derivatives,
such as doxycycline, to prevent diabetes-related alveolar bone loss or
osteo-integration in experimentally induced periodontitis (Alkan
et al., 2002; Kopman et al., 2005). No deﬁnitive studies have been car-
ried out to assess the long-term effects that a tetracycline derivative,
like doxycycline,might have on the prevention of bone loss and fragility
associated with T1D. Herein, we have used a well-described mouse
model of T1D (STZ-induced diabetes inmale DBA/2J mice) inwhich sig-
niﬁcant skeletal complications are observed, including diaphysial and
metaphysial microarchitectural changes, as well as enhanced risk to
fracture (Nyman et al., 2011). Diabetic mice were treated with long-
term doxycycline (10 weeks) to determine the ability of doxycycline
to prevent the development of diabetic bone disease (DBD) in this
model.
2. Materials and methods
2.1. Animal model
Male DBA/2J mice, 10–11 weeks of age, (The Jackson Laboratories,
Bar Harbor, Maine) were treated either with streptozotocin (STZ) to in-
duce diabetes (40mg/kg/day× 5 days) orwith vehicle (100mM citrate,
17J.L. Fowlkes et al. / Bone Reports 1 (2015) 16–19pH 4.5). At ~12–13 weeks of age, diabetic mice, as conﬁrmed by
glucosuria,were then randomly assigned to treatmentwith doxycycline
(DOX) rodent chow(STZ+DOX: Bio-Serv product #S3888, doxycycline
concentration of 200 mg/kg, Frenchtown, NJ; n = 20) or with a control
(CON) chow for doxycycline diets (STZ + CON: Bio-Serv product
#S4207; n = 20). Vehicle-treated (non-diabetic) mice were similarly
fed, receiving either doxycycline chow (VEH+DOX; n=10) or control
chow (VEH + CON; n = 10). Mice were provided ad libitum access to
water and to their assigned food. Food consumption and body weight
(Table 1) were measured weekly for the next 10 weeks. Blood glucose
was measured on trunk blood at sacriﬁce via glucometer (OneTouch®
Ultra®2 Blood Glucose Monitoring System, LifeScan, Inc., Milpitas, CA;
average intra-assay coefﬁcient of variation of 1.7% across a range of
40–300 mg/dl target glucose concentrations). All procedures were ap-
proved by the Institutional Animal Care and Use Committee at the Uni-
versity of Arkansas for Medical Sciences.
2.2. Skeletal assessment
After euthanasia, the left femurwas harvested and femur lengthwas
measured using calipers. Bones were ﬂash frozen with liquid nitrogen
and stored at−80 °C until analysis.With each femur immersed in phos-
phate buffered saline (PBS) at room temperature, the long axis of the
bone was aligned with the scanning axis of the μCT40 (Scanco Medical,Table 1
Phenotypic parameters (top); and selected properties of bone (metaphysis and diaphysis), as d
STZ + DOX (A) STZ + CON (B) V
n = 20 n = 19c n
Parameter
Starting body weight Grams 23.53 (1.79) 23.82 (1.73)
Ending body weightc Grams 22.71 (2.28) 23.07 (1.81)
Week 5 food intake gm/mouse/day 10.81 (1.39) 9.64 (2.85)
Week 10 food intake gm/mouse/day 7.59 (0.67) 7.26 (1.18)
Blood glucosec mg/dL 570.63 (70) 594 (12.6)
Serum bone biomarkers
P1NPc ng/mL 6.20 (1.80) 4.46 (1.27)
RatLAPSc ng/mL 31.10 (22.02) 22.42 (9.21)
Metaphysis (trabecular bone)
VOX-BV/TV mm3 0.06 (0.01) 0.06 (0.01)
Conn.D mm−3 53.94 (19.31) 66.92 (20.73)
Tb.N mm−1 3.46 (0.26) 3.59 (0.25)
Tb.Th mm 0.04 (0.003) 0.04 (0.002)
Tb.Sp mm 0.29 (0.02) 0.28 (0.02)
SMIa – 2.82 (0.21) 2.78 (0.21)
Tb.TMD mgHA/cm3 863.52 (25.3) 860.15 (25.99)
Diaphysis (cortical bone)
Length mm 13.76 (0.3) 13.84 (0.2)
Ma.V mm3 0.56 (0.05) 0.54 (0.04)
Ct.Ar mm2 0.65 (0.06) 0.69 (0.07)
Tt.Ar mm2 1.12 (0.08) 1.15 (0.07)
Imin mm4 0.05 (0.01) 0.06 (0.01)
Ct.Th mm 0.21 (0.01) 0.22 (0.02)
Ct.TMD mgHA/cm3 1346.34 (11.67) 1357.64 (18.04) 1
Ct.Po % 3.07 (0.21) 2.92 (0.27)
Slendernessb mm/mm2 12.35 (0.79) 12.1 (0.56)
Stiffness N/mm 81.94 (18.54) 88.5 (19.04)
Peak force N 15.6 (2.52) 16.58 (2.7)
Work-to-fracture N mm 3.56 (1.09) 3.52 (1.5)
Modulus GPa 16.16 (3.17) 16.36 (2.92)
Bending strength MPa 274.96 (34.01) 275.07 (33.01)
Toughness N/mm 5.46 (1.53) 5.07 (2.09)
a Structural model index characterizes the shape of trabecular bone (1: plate-like; 3: rod-lik
b Slenderness is the ratio of the length to the total cross-sectional area of the femur mid-sh
telopeptides of type I collagen; BV/TV, bone volume/tissue volume; Conn.D, connectivity densit
structural model index; Tb.TMD, trabecular tissue mineral density; Ma.V, marrow volume; Ct
thickness; Ct.TMD, cortical tissue mineral density; Ct.Po, cortical porosity. Signiﬁcant differenc
c n = 19 for STZ + CON, for the four marked variables, due to animal demise on study endBrüttisellen, Switzerland). All scans were acquired at an isotropic voxel
size of 12 μmusing the same energy settings (70 kVp/0.114mA), acqui-
sition parameters (integration time of 300mswith 1000 projections per
full rotation), and calibration to a hydroxyapatite (HA) phantom with a
beam hardening correction from ScancoMedical, as we have previously
described (Nyman et al., 2011). The regions of interest (ROI) included
the trabecular bone of the metaphysis (0.24–1.4 mm above the growth
plate) and the cortical bone of the mid-shaft (1.19 mm in length span-
ning the mid-point between the condyles and femoral neck). Each ROI
had a unique threshold (323mgHA/cm3 and 809mgHA/cm3 for trabec-
ular and cortical bone, respectively) and Gaussian noise ﬁlter (sigma of
0.6 with support of 1 for trabecular bone and sigma of 0.8 with support
of 2 for cortical bone) that was used for all scans. Standard evaluation
scripts from themanufacturer were used to determine the architectural
and structural properties of trabecular and cortical bone, respectively.
Moreover, in calculation of tissuemineral density (TMD), partial volume
effects were suppressed by peeling the ﬁrst voxel from all surfaces fol-
lowing segmentation of the bone.
2.3. Biomechanical testing
To determine the differences in bone strength between groups, a
pre-load (1 N) held each hydrated femur in place on the lower support
points of a three-point bending ﬁxture with the anterior side downetermined by μCT and three-point bending.
P values
EH + DOX (C) VEH + CON (D) Doxycycline Diabetes
= 10 n = 10 A vs. B C vs. D A vs. C B vs. D
23.05 (1.27) 24.89 (2.01) 0.96 0.09 0.96 0.36
31.84 (3.37) 31.98 (2.77) 1.00 1.00 b .0001 b .0001
4.81 (0.36) 5.11 (0.42) 0.16 0.69 b .0001 b .0001
4.53 (0.43) 4.69 (0.46) 0.45 0.67 b .0001 b .0001
129.6 (21.82) 123.7 (22.75) 0.20 0.76 b .0001 b .0001
15.62 (3.72) 13.33 (2.72) 0.04 0.04 b .0001 b .0001
8.03 (1.28) 9.21 (3.05) 0.12 0.85 0.0003 0.054
0.09 (0.02) 0.1 (0.02) 0.13 0.10 b .0001 b .0001
59.91 (24.37) 73.98 (16.22) 0.20 0.38 0.75 0.75
3.7 (0.4) 3.91 (0.26) 0.21 0.21 0.11 0.02
0.05 (0.001) 0.05 (0.003) 0.61 0.82 b .0001 b .0001
0.27 (0.03) 0.25 (0.02) 0.25 0.25 0.02 0.01
2.78 (0.22) 2.61 (0.16) 1.00 0.21 1.00 0.15
934.46 (6.99) 927.36 (19.73) 0.97 0.97 b .0001 b .0001
13.76 (0.23) 13.8 (0.34) 1.00 1.00 1.00 1.00
0.53 (0.04) 0.53 (0.04) 0.51 1.00 0.25 1.00
0.81 (0.06) 0.85 (0.08) 0.07 0.18 b .0001 b .0001
1.25 (0.07) 1.29 (0.10) 0.45 0.45 0.0002 b .0001
0.07 (0.01) 0.07 (0.01) 0.30 0.30 b .0001 b .0001
0.25 (0.02) 0.26 (0.02) 0.03 0.25 b .0001 b .0001
372.08 (16.51) 1368.74 (20.74) 0.11 0.65 0.0006 0.18
2.56 (0.15) 2.58 (0.16) 0.06 0.77 b .0001 0.0006
11.05 (0.6) 10.74 (0.88) 0.57 0.57 b .0001 b .0001
108.74 (10.18) 116.43 (13.19) 0.46 0.46 0.0004 0.0003
19.42 (1.96) 21.03 (2.02) 0.29 0.29 0.0005 b .0001
3.8 (1.24) 4.49 (0.46) 1.00 0.62 1.00 0.17
16.68 (2.51) 16.96 (2.82) 1.00 1.00 1.00 1.00
282.9 (33.75) 290.58 (24.31) 1.00 1.00 1.00 0.89
4.72 (1.39) 5.37 (0.84) 1.00 1.00 0.98 1.00
e).
aft. Abbreviations: P1NP, procollagen type 1 N-terminal propeptide; RatLAPS, C-terminal
y; Tb.N, trabecular number; Tb.Th, trabecular thickness; Tb.Sp, trabecular separation; SMI,
.Ar, cortical area; Tt.Ar, total cross-sectional area; Imin, moment of inertia; Ct.Th, cortical
es (P b 0.05) are highlighted in bold font.
date.
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lower supports was 8 mm, and the load rate was 3.0 mm/min. Then,
forces from a 100N load cell (Honeywell, Morristown, NJ) and displace-
ments from the LVDT (Dynamight 8841, Instron, Canton, OH) were re-
corded at 50 Hz during a monotonic load-to-failure test. Measured
differences in biomechanical properties included stiffness and the
peak force endured by the bone. Material properties of modulus and
strength of the cortex were also estimated using standard beam theory
(Nyman et al., 2011). The μCT scans provided the moment of inertia
(Imin) and the distance between the neutral axis of bending and the out-
ermost point in the anterior–posterior direction (Cmin).
2.4. Bone biomarker analyses
Procollagen type 1 N-terminal propeptide (P1NP), a marker of bone
formation, was measured in serum at sacriﬁce, using the Rat/Mouse
P1NP Enzyme immunoassay (Immunodiagnostics Systems, Inc., Fountain
Hills, AZ; #AC-33F1). Serum C-terminal telopeptides of type I collagen
(RatLAPS), amarker of bone resorption, wasmeasured using the RatLAPs
ELISA (Immunodiagnostics Systems, Inc., Fountain Hills, AZ; #AC-06F1).
2.5. Statistical analyses
A one-way analysis of variance (ANOVA) was performed to test
whether the means of bone biomarkers and bone parameters were
equal between the four groups: STZ + DOX, STZ + CON, VEH + DOX,
and VEH + CON. Linear contrasts for the group variable were used to
test the following four pairwise comparisons: STZ + DOX vs. STZ +
CON, VEH + DOX vs. VEH + CON, STZ + DOX vs. VEH + DOX, and
STZ+CONvs. VEH+CON. For each parameter, a step-downBonferroni
method was used to keep the overall family-wise error rate under 0.05
to adjust formultiple comparisons. An analysis of covariance (ANCOVA)
model was used to compare the mean cortical thickness (Ct.Th) be-
tween STZ + DOX and STZ + CON groups, after adjusting for RatLAPS.
All tests were two-sided assuming a signiﬁcance level of 5%. All statisti-
cal analyseswere generated using SAS/STAT software, Version 9.4 of the
SAS System for Windows 7, Copyright © 2002–2012 SAS Institute Inc.
3. Results and discussion
Changes in body weight, food consumption and blood glucose across
the ten-week treatment period are shown in Table 1. No statistically sig-
niﬁcant differences in average starting body weight existed between
mice in each of the four groups (overall ANOVA, P = 0.11). Both non-
diabetic groups (VEH + DOX, VEH + CON) consumed comparable
amounts of food, by weight, over time (P = 0.69 for week 5; P = 0.67
for week 10). Moreover, by week ten, ﬁnal body weights (P = 1) and
ﬁnal blood glucose levels (P = 0.76) were not signiﬁcantly different be-
tween these twonon-diabetic groups. However, as expected, both groups
of diabetic DBA/2J mice (STZ + DOX, STZ + CON), when assessed after
10weeks of diabetes, demonstrated polyphagia (approximately double
the food consumption relative to control groups; P b 0.0001 for STZ +
DOX vs. VEH+DOX and STZ+ CON vs. VEH+ CON), severe hypergly-
cemia (P b 0.0001 for both comparisons) andweight loss (P b 0.0001 for
both comparisons; Table 1). Hence, based on the changes in average
weekly food consumption and in bodyweight over time, thedoxycycline
dose during the 10 week treatment period for mice in the STZ + DOX
group ranged from ~92 mg/kg/day (at week 5) to 67 mg/kg/day
(week 10) and in the VEH + DOX group ranged from 42 mg/kg/day
(week 5) to 28 mg/kg/day (week 10).
Selected bone parameters, as determined by serum bone biomarker
assays, μCT, and biomechanical testing are also shown in Table 1.
Serum P1NP values were signiﬁcantly lower in diabetic mice (STZ +
DOX vs. VEH + DOX and STZ + CON vs. VEH + CON, P b 0.0001 for
both), indicating that long-term diabetes was characterized by a signiﬁ-
cant reduction in bone formation. Serum RatLAPS values weresigniﬁcantly higher in doxycycline-treated diabetic mice, compared
with non-diabetic mice (STZ + DOX vs. VEH + DOX, P b 0.0001) and
demonstrated a similar, nearly signiﬁcant, trend in control-fed mice
(STZ + CON vs. VEH + CON, P = 0.054), reﬂecting a disease-
associated increase in bone resorption. Interestingly, doxycycline
treatment itself, both in the diabetic mice and in the control mice, in-
creased P1NP values (STZ + DOX vs STZ + CON and VEH + DOX and
VEH+CON, P=0.04 for both), suggesting amodest positive drug treat-
ment effect on osteoblast function. RatLAPS values, however, were not
further affected by doxycycline treatment.
When examining bone quality, consistent with our previous ﬁnd-
ings (Nyman et al., 2011) long-term diabetes was associated with deﬁ-
cits in trabecular bone microarchitecture, including decreases in
trabecular bone volume fraction (BV/TV; P b 0.0001), trabecular thick-
ness (P b 0.0001), and trabecular TMD (P b 0.0001). In cortical bone,
deﬁcits in cortical bone area (P b 0.0001), cortical thickness (P b
0.0001), cortical TMD (P = 0.0006 for STZ + DOX vs. VEH + DOX),
Imin (P b 0.0001), and bone stiffness (P = 0.0004 for STZ + DOX
vs. VEH+DOX; P=0.0003 for STZ+CONvs. VEH+CON)were appar-
ent in diabetic animals, in addition to an increase in cortical porosity
(P b 0.0001 for STZ + DOX vs. VEH + DOX; P = 0.0006 for STZ +CON
vs. VEH + CON). Femur slenderness, the ratio of the length to the
total cross-sectional area of the femur mid-shaft, was also increased
in diabetic animals (P b 0.0001 for STZ + DOX vs. VEH + DOX and
STZ + CON vs. VEH + CON). Consequently, diabetes caused a decrease
in the structural strength of the femur in bending (peak force; P=0.0005
for STZ + DOX vs. VEH + DOX; P b 0.0001 for STZ + CON vs. VEH +
CON). However, no signiﬁcant differences were identiﬁed in any of the
measured microarchitectural or biomechanical bone parameters
between doxycycline-treated and control-fed non-diabetic mice
(VEH + DOX, VEH + CON, respectively). Moreover, when compar-
ing doxycycline-treated and control-fed diabetic mice (STZ + DOX,
STZ + CON, respectively), a modest further decrement in cortical
thickness was observed in the STZ + DOX group (P = 0.03). This dif-
ference was not explained by differences in body weight; however,
mean ratLAPs values were higher in the STX + DOX group and Ct.Th
was negatively associated with ratLAPS among the diabetic mice
(r =−0.33, p = 0.045), inferring slightly greater bone resorption in
the STZ + DOX group. After adjusting for ratLAPS, Ct.Th was not
signiﬁcantly different between the STZ + DOX and STZ + CON groups
(P = 0.052). All other microarchitectural and biomechanical parame-
ters were unaffected by doxycycline exposure. Hence, doxycycline
treatment, in this model of male mice, did not prevent or alleviate
the development of diabetic bone disease, as determined by
microarchitectural analysis and biomechanical testing, even when
given at twice the exposure dose relative to control animals.
Similar to our ﬁndings in animal models (Nyman et al., 2011), dete-
rioration in trabecular bone microarchitecture, in particular, has been
inferred from studies of T1D subjects with a history of fracture. Our ex-
pectation that tetracycline derivatives might improve bone deﬁcits in
diabetes comes from experiments demonstrating that, in other in vivo
models of diabetes, tetracyclines can: 1) increase osteoblast-speciﬁc
collagen synthesis (Sasaki et al., 1992); 2)maintain normal bone forma-
tion rates and prevent trabecular bone loss (Bain et al., 1997); and 3) in-
hibit proinﬂammatory mediators (Golub et al., 1998). Additionally, in
women with post-menopausal systemic osteoporosis, the use of sub-
antimicrobial dose doxycycline (SDD) has also been shown to signiﬁ-
cantly reduce serum biomarkers of bone resorption and of inﬂamma-
tion (Payne and Golub, 2011; Payne et al., 2011). In the present study,
however, we found no evidence for improvement in diabetic bone def-
icits by doxycycline.
These negative ﬁndings do, nevertheless, merit attention. Recent
studies demonstrating that doxycycline can inhibit M2-type (alterna-
tively activated) macrophage polarization and pathologic neovasculari-
zation suggest a potential therapeutic role for doxycycline in conditions
of pathological angiogenesis (He and Marneros, 2014), including
19J.L. Fowlkes et al. / Bone Reports 1 (2015) 16–19diabetic complications such as retinopathy, as conﬁrmed in a recent
proof-of-concept clinical trial (Scott et al., 2014). Hence, the lack of a sig-
niﬁcant detrimental effect of long-termexposure on diabetic skeletal tis-
sue is important to note, should chronic doxycycline therapy become a
reality. Equally, the absence of any detrimental effect of long-term
doxycycline exposure on healthy skeletal tissues is a pertinent ﬁnding
for experimentalmodels employing tissue-speciﬁc doxycycline repress-
ible Cre-recombinase gene expression methodologies, especially those
that target skeletal tissues (e.g., Osterix-Cre) (Elefteriou and Yang,
2011). Doxycycline delivery via rodent chow, at a concentration of
200mg/kg aswas used in this experiment, is the recommended delivery
route for these doxycycline regulated gene expression systems
(Cawthorne et al., 2007).
4. Conclusions
While the tetracycline class of antibiotics has been shown to have
beneﬁcial effects on boney tissues in models of diabetes, in male DBA/
2J mice subjected to 10 weeks of diabetes, diabetic bone disease was
not improved by doxycycline treatment. Moreover, long-term doxycy-
cline exposure was not deleterious to the microarchitecture or biome-
chanical properties of healthy bone in male DBA/2J mice.
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